d center news from FierceBiotech

PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the Read more...

The FDA have given a thumbs down to Genzyme's request for permission to sell its Pompe disease drug Read more...

The Translational Accelerator has opened its doors to all biotech companies in Arizona--or any life sciences company thinking about moving there. And it has $20 million in venture funds to welcome Read more...

GlaxoSmithKline is sinking $100 million into a neuroscience research center in China that will play a Read more...

Pima County, Arizona has scored a big win on the economic development front with the newly begun construction of a new, Read more...

Press Release: DuPont Plans New R&D Center in Hyderabad, India

Read more...

DuPont has unveiled plans to invest almost $23 million in a new R&D center in Hyderabad, India. The site initially will focus on molecular biology, bio-informatics and polymer synthesis, according to DuPont. DuPont has appointed Homi Bhedwar as director of the Knowledge Center.

"The establishment of the DuPont Knowledge Center in India is consistent with our company's strategy of going where the growth is," said Balvinder Singh Kalsi, president, DuPont India. "Our intent is to …

Read more...

Press Release: AstraZeneca Makes $100M Research Investment In Boston

Read more...

> Indianapolis-based Semafore Pharmaceuticals has completed a $9.5 million second round of venture financing. Much of the money will be used to advance Semafore's clinical program for SF1126, its lead PI3 Kinase inhibitor for the treatment of cancer. "This is an exciting time for Semafore, as we prepare to initiate Phase l clinical trials of our lead PI3 Kinase inhibitor SF1126 and transition into a clinical stage company," said John Sima, interim CEO and COO of Semafore. …

Read more...

Bayer will slash hundreds of jobs as it shutters its research facility in West Haven, CN, as part of a global restructuring triggered by its takeover of Schering. About 600 research jobs will be cut in the U.S. with another 200 layoffs to come. In the future, Bayer Schering Pharma will concentrate R&D activities in Berlin and Wuppertal in Germany, and Berkeley, CA. By the end of 2008 the company expects to reduce its R&D costs by $210 million a year.

"The productivity of …

Read more...